Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

2.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

3.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

4.

When a Groundbreaking Cancer Therapy Causes Cancer.

5.

Study sheds light on challenges for women of color after breast cancer surgery


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot